Eleni Gavriilaki, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discussess the long-term safety and efficacy of allogeneic hematopoietic cell transplantation (alloHCT) in patients with myelofibrosis. Data from 12 patients was analyzed in a retrospective study, which reported that patients who received ruxolitinib following alloHCT did not suffer from treatment-related mortality, and that the two-year disease-free survival for patients who received ruxolitinib following alloHCT was 75%, compared to 14.3% for patients who did not receive ruxolitinib. Two-year overall survival was significantly improved in patients who received ruxolitinib following alloHCT. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
